Progress in Treating Chronic Kidney Disease Patients with Cardiovascular Disease: Kidney Health Initiative Develops Clinical Research Recommendations

Throughout the world, kidney disease is far more common than most people realize. It’s not a stretch to call it a “hidden epidemic,” as the number of people living with kidney disease (850 million) is roughly twice that of those living with diabetes.(1)

The health issue presented by chronic kidney disease (CKD) is magnified by the high prevalence of associated cardiovascular (CV) disease in these patients. Patients with CKD most commonly die from CV events.(2) Also, among patients with CV disease, 30 to 60 percent have kidney disease.(3)

Continue reading

Adjudicating Cardiovascular Endpoints in Diabetic Kidney Disease Studies

Diabetic kidney disease (DKD) patients have an increased cardiovascular (CV) risk in Diabetic Kidney Disease Covance Blogaddition to their increased risk of progression to end-stage renal disease. Recognizing that the FDA and other regulatory agencies have great interest in both the CV and renal safety and efficacy of compounds under development, pharmaceutical companies should consider inclusion of an appropriate approach to adjudication of potential CV events early in the course of planning for development of drugs to treat DKD.

Adapting current regulatory perspectives

From the regulatory perspective, there is a lot of emphasis focused on looking at both CV and renal risks during the development of type 2 diabetes treatments.1  However, no specific guidance exists for clinically-evident endpoints in DKD. Continue reading